Clinics in Chicago, Illinois

Illinois cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Illinois for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Chicago's medical research density also includes legitimate IND-based trials at academic institutions.

• Illinois Medical Practice Act of 1987, 225 ILCS 60
  Establishes physician licensure and discipline through the Illinois Department of Financial and Professional Regulation Medical Disciplinary Board.
• Illinois Pharmacy Practice Act, 225 ILCS 85
  Regulates compounding pharmacies aligned with federal 503A and 503B standards relevant to biologic preparation.
• Illinois Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505
  Empowers the Attorney General to pursue deceptive marketing claims against providers making unsupported clinical statements.

The FDA has issued warning letters to Illinois clinics offering stem cell, exosome, and umbilical cord-derived therapies. The Illinois Department of Financial and Professional Regulation has disciplined physicians for unprofessional conduct related to regenerative medicine. The Illinois Attorney General has used the Consumer Fraud and Deceptive Business Practices Act to pursue clinics making unsupported clinical claims, including class-action partnerships with private plaintiffs. Chicago's market draws ongoing federal attention. No statewide injunction parallel to the California SVF case has been issued, but enforcement risk remains material.